Literature DB >> 28935647

García-Sanz R. WM, MYD88, and CXCR4: following the thread. Blood. 2016;128(6):746-748.

.   

Abstract

Entities:  

Year:  2017        PMID: 28935647     DOI: 10.1182/blood-2017-07-798488

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  1 in total

1.  A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.

Authors:  Constantine S Tam; Stephen Opat; Shirley D'Sa; Wojciech Jurczak; Hui-Peng Lee; Gavin Cull; Roger G Owen; Paula Marlton; Björn E Wahlin; Ramón Garcia Sanz; Helen McCarthy; Stephen Mulligan; Alessandra Tedeschi; Jorge J Castillo; Jaroslaw Czyz; Carlos Fernández de Larrea; David Belada; Edward Libby; Jeffrey V Matous; Marina Motta; Tanya Siddiqi; Monica Tani; Marek Trneny; Monique C Minnema; Christian Buske; Veronique Leblond; Judith Trotman; Wai Y Chan; Jingjing Schneider; Sunhee Ro; Aileen Cohen; Jane Huang; Meletios Dimopoulos
Journal:  Blood       Date:  2020-10-29       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.